NCT03312556

Brief Summary

Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
8mo left

Started Sep 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Sep 2017Dec 2026

Study Start

First participant enrolled

September 21, 2017

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

October 12, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 17, 2017

Completed
8.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 21, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 21, 2026

Last Updated

November 6, 2025

Status Verified

November 1, 2025

Enrollment Period

9 years

First QC Date

October 12, 2017

Last Update Submit

November 4, 2025

Conditions

Keywords

hypertensionsupine hypertensionautonomic failurepure autonomic failuremultiple system atrophycpap

Outcome Measures

Primary Outcomes (1)

  • Supine Systolic Blood Pressure

    change in supine systolic blood pressure from baseline

    12 hours

Secondary Outcomes (1)

  • Urinary volume

    12 hours

Study Arms (2)

Placebo pill or patch or sham CPAP

PLACEBO COMPARATOR

Placebo pill or patch or sham CPAP

Drug: Placebo

CPAP (continuous positive airway pressure)

ACTIVE COMPARATOR

Continuous positive airway pressure during the night

Device: continuous positive airway pressure (CPAP)

Interventions

Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.

Also known as: CPAP
CPAP (continuous positive airway pressure)

Placebo pill or patch. Single dose

Also known as: placebo pill or patch
Placebo pill or patch or sham CPAP

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with autonomic failure and with supine hypertension from all races

You may not qualify if:

  • All medical students
  • Pregnant women
  • High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction)
  • History of serious allergies or asthma.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Autonomic Dysfunction Center/ Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

RECRUITING

Related Publications (1)

  • Okamoto LE, Celedonio JE, Smith EC, Paranjape SY, Black BK, Wahba A, Park JW, Shibao CA, Diedrich A, Biaggioni I. Continuous Positive Airway Pressure for the Treatment of Supine Hypertension and Orthostatic Hypotension in Autonomic Failure. Hypertension. 2023 Mar;80(3):650-658. doi: 10.1161/HYPERTENSIONAHA.122.20081. Epub 2023 Jan 5.

MeSH Terms

Conditions

Pure Autonomic FailureHypertensionMultiple System AtrophyMicrocephaly, Primary Autosomal Recessive, 6

Interventions

Continuous Positive Airway Pressure

Condition Hierarchy (Ancestors)

Primary DysautonomiasAutonomic Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Positive-Pressure RespirationRespiration, ArtificialAirway ManagementTherapeuticsRespiratory Therapy

Study Officials

  • Italo Biaggioni, MD

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bonnie K Black, RN

CONTACT

Luis E Okamoto, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine and Pharmacology

Study Record Dates

First Submitted

October 12, 2017

First Posted

October 17, 2017

Study Start

September 21, 2017

Primary Completion (Estimated)

September 21, 2026

Study Completion (Estimated)

December 21, 2026

Last Updated

November 6, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations